Characteristic | Balsalazide | Mesalazine 0.5 g tid (n=44) | |||||
---|---|---|---|---|---|---|---|
1.5 g bid (n=49) | 3.0 g bid (n=40) | ||||||
Duration of UC symptoms (y) | 8.5 (0–36) | 8.4 (0–29) | 6.7 (0–32) | ||||
Time in remission (months) | 2.4 (0–10) | 2.4 (0–9) | 2.3 (0–10) | ||||
No of previous UC attacks | 6.6 (2–20) | 7.7 (2–26) | 7.2 (2–20) | ||||
5-ASA use prior to study (n) | 22 | 19 | 23 | ||||
CAI | 1.1 (0–7) | 1.2 (0–4) | 1.1 (0–5) | ||||
Endoscopic score | 2.0 (0–8) | 1.9 (0–8) | 1.6 (0–8) | ||||
Extension of inflammation | |||||||
Procto-sigmoiditis (n (%)) | 10 (20.8) | 12 (30.0) | 12 (30.0) | ||||
Left sided (n (%)) | 19 (39.5) | 11 (27.5) | 13 (29.5) | ||||
Subtotal (n (%)) | 9 (18.7) | 6 (15.0) | 10 (22.7) | ||||
Total (n (%)) | 10 (20.8) | 11 (27.5) | 9 (20.4) | ||||
Histological findings | |||||||
Normal (n (%)) | 3 (6.2) | 5 (12.5) | 6 (13.6) | ||||
UC: remission (n (%)) | 29 (60.4) | 20 (50.0) | 26 (59.0) | ||||
UC: mildly active (n (%)) | 8 (16.6) | 12 (30.0) | 8 (18.1) | ||||
UC: moderately active (n (%)) | 7 (14.5) | 1 ( 2.5) | 3 ( 6.8) | ||||
UC: highly active (n (%)) | 1 ( 2.0) | 2 ( 5.0) | 1 ( 2.2) |
Values are mean (range) or number (%).
CAI, clinical activity index.